OpGen (OPGN: NASDAQ) Investor Relations Material

Overview

Precision medicine company OpGen, Inc. is making waves in the field of molecular microbiology solutions, with a diverse range of products aimed at combatting infectious diseases. Its cutting-edge offering includes the Acuitas AMR Gene Panel, an in vitro diagnostic test used for the identification of antimicrobial resistance in bacterial colonies from any specimen, and the Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. In addition, OpGen, Inc.'s products feature advanced technology solutions such as the ARES Technology Platform and the Unyvero Platform, which use AI-powered bioinformatics solutions and automated sample-to-answer molecular diagnostics to help healthcare professionals detect and manage infections. The Company's work has garnered significant attention, with collaborative efforts in association with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program focused on tracking and managing antimicrobial-resistant infections at healthcare institutions. Headquartered in Rockville, Maryland, OpGen, Inc. was founded in 2001 and continues to pave the way in the field of molecular microbiology solutions.